Access Statistics for Izabela Jelovac

Author contact details at EconPapers.

Working Paper File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Basic, applied research, and price negotiation for new drugs 0 0 0 0 0 0 0 17
Comparing Organizational Structures in Health Services 0 0 0 0 0 1 4 2,393
Comparing approval procedures for new drugs 0 0 0 0 0 0 1 24
Comparing organizational structures in health services 0 0 0 0 0 1 1 2
Demand versus Supply Side Cost-Sharing: Patients’ preferences 0 0 0 0 0 0 1 19
Demand versus Supply Side Cost-Sharing: The users' perspective 0 0 0 0 0 0 1 16
Demand versus Supply Side Cost-Sharing: The users' perspective 0 0 0 0 0 0 0 21
Des « Nobels » de sciences économiques au service des systèmes de santé 0 0 0 0 0 0 1 14
Des « Nobels » de sciences économiques au service des systèmes de santé 0 0 0 0 0 0 0 0
Do free-of-charge public health services impede cost recovery policies in Khartoum state, Sudan? 0 0 0 7 1 1 1 91
Drug approval decision times, international reference pricing and access to new drugs 0 0 0 0 1 1 3 23
Drug approval decision times, international reference pricing and strategic launches of new drugs 0 0 0 0 0 0 0 33
Drug approval decision times, international reference pricing and strategic launches of new drugs 0 0 0 0 0 0 0 28
Drug approval decision times, international reference pricing and strategic launches of new drugs 0 0 0 0 0 0 1 33
Drug approval decision times, international reference pricing and strategic launches of new drugs 0 0 0 0 0 0 0 36
Drug approval decision times, international reference pricing and strategic launches of new drugs 0 1 2 10 0 2 6 61
Drug approval decision times, international reference pricing and strategic launches of new drugs 0 0 0 0 1 1 7 37
Drug approval decision times, international reference pricing and strategic launches of new drugs 0 0 0 0 0 0 0 34
Drug approval decision times, international reference pricing and strategic launches of new drugs 0 0 0 11 0 0 1 57
Drug launch timing and international reference pricing 0 0 0 17 0 0 0 89
Drug launch timing and international reference pricing 0 0 0 0 0 0 1 46
Drug launch timing and international reference pricing 0 0 0 0 0 0 0 21
Drug launch timing and international reference pricing 0 0 1 35 0 0 1 67
Drug launch timing and international reference pricing 0 0 0 0 0 0 0 25
Drug launch timing and international reference pricing 0 0 0 0 0 0 1 22
Drug launch timing and international reference pricing 0 0 0 0 1 1 1 52
Enjeux tarifaires de la médecine génomique 0 0 0 0 0 0 0 18
External Reference Pricing and Sequential Launching of Drugs 0 0 0 0 0 0 0 35
External referencing and pharmaceutical price negotiation 0 0 0 152 0 0 0 459
External referencing and pharmaceutical price negotiation 0 0 0 10 0 0 0 39
External referencing and pharmaceutical price negotiation 0 0 0 0 0 0 1 28
GPs’ Payment Contracts and their Referral Policy 0 0 0 14 0 0 1 102
GPs’ payment contracts and their referral practice 0 0 0 0 0 0 1 1
Health Services: Incentives and Access. Keynote speech 0 0 0 0 0 0 0 20
Health services: Incentives and access 0 0 0 0 0 1 1 19
Healthcare providers’ payments with personalized medicine 0 0 0 0 0 0 0 9
Household health-seeking behaviour in Khartoum, Sudan: The willingness to pay for public health services if these services are of good quality 0 0 1 1 0 0 1 4
How Should Donors Give Foreign Aid? Project Aidversus Budget Support 0 0 0 63 0 0 1 375
How should donors give foreign aid ? A theoretical comparison of aid modalities 0 0 0 0 0 0 0 17
How should donors give foreign aid? Project aid versus budget support 0 0 0 111 0 0 0 277
How should donors give foreign aid? Project aid versus budget support 0 0 0 171 2 2 7 650
Incentives to patients versus incentives to health care providers: The users' perspective 0 0 0 17 0 0 1 41
Incentives to patients versus incentives to health care providers: The users' perspective 0 0 0 0 0 0 0 25
Incentives to patients versus incentives to health care providers: The users' perspective 0 0 0 0 0 0 0 34
Incentives to patients versus incentives to health care providers: The users’ perspective 0 0 0 27 0 0 0 61
La Médecine personnalisée 0 0 0 0 0 0 0 32
Médecine personnalisée et prix des médicaments 0 0 0 0 0 1 2 23
On the relationship between the negociated price of pharmaceuticals and the patients' co-payment 0 0 0 0 0 1 2 36
On the relationship between the negociated price of pharmaceuticals and the patients' co-payment 0 0 0 0 0 0 2 65
Payment mechanism and GP self-selection: capitation versus fee for service 0 0 0 0 0 0 0 54
Perception du lien entre mode de rémunération et comportement des médecins 0 0 0 0 0 0 1 28
Perception du lien entre mode de rémunération et comportement des médecins 0 0 0 0 0 0 1 30
Personalized medicine and drug prices 0 0 0 0 0 0 1 43
Physicians Balance Billing, Supplemental Insurance and Access to Health Care 0 0 0 0 0 0 1 29
Physicians Balance Billing, Supplemental Insurance and Access to Health Care 0 0 0 0 0 0 0 40
Physicians Balance Billing, Supplemental Insurance and Access to Health Care 0 0 0 0 0 0 1 44
Physicians Balance Billing, Supplemental Insurance and Access to Health Care 0 0 0 0 0 0 0 46
Physicians self selection of a payment mechanism: Capitation versus fee-for-service 0 0 0 30 0 2 4 290
Physicians self selection of a payment mechanism: Capitation versus fee-for-service 0 0 0 31 0 0 0 89
Physicians' Balance Billing, Fees Negotiations and Supplementary Insurance 0 0 0 0 0 0 1 13
Physicians' Balance Billing, Fees Negotiations and Supplementary Insurance 0 0 0 0 0 0 0 13
Physicians' Balance Billing, Fees Negotiations and Supplementary Insurance 0 0 0 0 0 0 0 11
Physicians' balance billing, supplemental insurance and access to health care 0 0 1 15 1 2 5 89
Physicians’ balance billing, supplemental insurance and access to health care 0 0 0 27 0 0 0 114
Physicians’ balance billing, supplemental insurance and access to health care 0 0 0 0 0 0 1 54
Preferences for Demand versus Supply Side Cost-Sharing 0 0 0 0 0 0 0 13
Pricing and Welfare Implications of Parallel Imports in the Pharmaceutical Industry 0 0 2 3 0 0 6 9
Pricing and Welfare of Parallel Imports in the Pharmaceutical Industry 0 0 0 165 0 0 0 443
Primary Care, Gatekeeping and Incentives 0 0 0 0 0 1 7 94
Regulation and Altruism 0 0 0 29 0 0 1 48
Regulation and Altruism 0 0 0 25 0 0 0 35
Regulation and altruism 0 0 0 27 0 0 0 40
Regulation and altruism 0 0 0 9 1 1 1 36
Research funding and price negotiation for new drugs 0 0 0 0 0 0 0 10
Research funding and price negotiation for new drugs 0 0 0 0 0 1 1 8
Research funding and price negotiation for new drugs 0 0 0 0 0 0 0 18
Research funding and price negotiation for new drugs 0 0 0 0 0 0 0 4
Research funding and price negotiation for new drugs 0 0 0 0 1 1 1 19
Research funding and price negotiation for new drugs 0 2 2 55 1 3 6 45
Research funding and price negotiation for new drugs 0 0 0 0 0 0 1 6
Research funding and price negotiation for new drugs 0 0 0 47 0 0 0 21
The pricing of physicians' services with distant medicine and health insurance 0 0 1 8 0 0 3 28
The pricing of physicians' services with distant medicine and health insurance 0 1 1 6 0 1 3 9
Treatment and referral decisions under different physician payment mechanisms 0 0 0 39 0 0 3 106
Total Working Papers 0 4 11 1,162 10 25 101 7,610


Journal Article File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Comparing approval procedures for new drugs 0 0 0 9 0 0 1 23
Comparing organizational structures in health services 0 0 0 125 1 2 2 365
Drug Launch Timing and International Reference Pricing 0 0 0 11 0 0 0 38
External referencing and pharmaceutical price negotiation 0 0 0 40 1 2 4 180
GPs' payment contracts and their referral practice 0 0 0 85 0 0 2 297
Household health-seeking behaviour in Khartoum, Sudan: The willingness to pay for public health services if these services are of good quality 0 0 0 34 0 0 1 134
How Should Donors Give Foreign Aid? A Theoretical Comparison of Aid Modalities 0 0 0 16 0 0 1 37
Incentives to patients versus incentives to health care providers: The users' perspective 0 0 1 6 0 0 1 23
On the relationship between the negotiated prices of pharmaceuticals and the patients' co-payment 0 0 2 41 1 1 6 127
Payment mechanism and GP self-selection: capitation versus fee for service 0 0 0 20 0 0 2 221
Physicians' payment contracts, treatment decisions and diagnosis accuracy 0 0 1 3 1 1 3 196
Physicians’ balance billing, supplemental insurance and access to health care 0 0 1 12 0 0 3 66
Pricing and Welfare Implications of Parallel Imports in the Pharmaceutical Industry 0 1 1 129 0 1 2 332
Regulation and altruism 0 0 0 0 0 0 0 19
Research funding and price negotiation for new drugs 0 0 0 4 0 1 1 34
Treatment and referral decisions under different physician payment mechanisms 0 0 0 19 0 1 3 112
Total Journal Articles 0 1 6 554 4 9 32 2,204


Statistics updated 2025-06-06